Form 4 for TRDA Entrada Therapeutics, Inc.

Accepted 2022-03-03 00:00:00 ET · period of report 2022-03-01 · accession 0001104659-22-030008 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2022-03-03	2022-03-01	TRDA	Sethuraman Natarajan	CSO	A - Grant	$0.00	+11.6K	156.3K	+8%	$0
D	2022-03-03	2022-03-01	TRDA	Sethuraman Natarajan	CSO	A - Grant	$0.00	+69.5K	69.5K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2022-03-01	A	A	11,588	$0.00	156,350	D	—	—	(F1) Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2023; (ii) 25% on March 1, 2024; (iii) 25% on March 1, 2025 and (iv) the remaining 25% on March 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. (F2) Consists of (i) 118,836 shares of common stock, (ii) 25,926 shares of restricted common stock issued upon early exercise of stock options, and (iii) 11,588 RSUs reported in this transaction.
2	Derivative	Stock Option (Right to Buy)	2022-03-01	A	A	69,525	$0.00	69,525	D	$11.57 · — to 2032-03-01	69,525 Common stock	(F3) 25% of the option shares shall vest and become exercisable on March 1, 2023, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2026.